

# Maria Giovanna Lupo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4424282/publications.pdf>

Version: 2024-02-01

41  
papers

765  
citations

566801

15  
h-index

552369

26  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1208  
citing authors

#	ARTICLE	IF	CITATIONS
1	PCSK9 induces a pro-inflammatory response in macrophages. <i>Scientific Reports</i> , 2018, 8, 2267.	1.6	166
2	Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia. <i>Pharmacological Research</i> , 2020, 153, 104653.	3.1	54
3	Naturally Occurring PCSK9 Inhibitors. <i>Nutrients</i> , 2020, 12, 1440.	1.7	43
4	Tuning the cytotoxicity of ruthenium(ii) para-cymene complexes by mono-substitution at a triphenylphosphine/phenoxydiphenylphosphine ligand. <i>Dalton Transactions</i> , 2017, 46, 16589-16604.	1.6	42
5	Exploring the Anticancer Potential of Diiron Bis-cyclopentadienyl Complexes with Bridging Hydrocarbyl Ligands: Behavior in Aqueous Media and <i>In Vitro</i> Cytotoxicity. <i>Organometallics</i> , 2020, 39, 645-657.	1.1	38
6	Angiotensin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects. <i>Journal of Cardiovascular Development and Disease</i> , 2018, 5, 39.	0.8	36
7	Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 578-588.	0.8	36
8	Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study. <i>Atherosclerosis</i> , 2020, 309, 39-46.	0.4	29
9	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9. <i>American Journal of Pathology</i> , 2020, 190, 2226-2236.	1.9	26
10	Current Evidence and Future Perspectives on Pharmacological Treatment of Calcific Aortic Valve Stenosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8263.	1.8	24
11	Peptide modulators of Rac1/Tiam1 protein-protein interaction: An alternative approach for cardiovascular diseases. <i>Peptide Science</i> , 2018, 110, e23089.	1.0	21
12	From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1843-1851.	0.8	19
13	PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3134.	1.0	19
14	Monofunctional Pt <sup>II</sup> Complexes Based on 8-Aminoquinoline: Synthesis and Pharmacological Characterization. <i>European Journal of Inorganic Chemistry</i> , 2019, 2019, 3389-3395.	1.0	18
15	The influence of D-chiro-inositol and D-myo-inositol in pregnant women with glucose intolerance. <i>Biomedical Reports</i> , 2017, 7, 169-172.	0.9	17
16	16p11.2 microdeletion syndrome: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 90.	0.4	16
17	Electrospinning of pyrazole-isothiazole derivatives: nanofibers from small molecules. <i>RSC Advances</i> , 2019, 9, 20565-20572.	1.7	16
18	Differential effects of red yeast rice, <i>Berberis aristata</i> and <i>Morus alba</i> extracts on PCSK9 and LDL uptake. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 1245-1253.	1.1	16

#	ARTICLE	IF	CITATIONS
19	Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2018, 1863, 991-997.	1.2	14
20	PCSK9 promotes arterial medial calcification. <i>Atherosclerosis</i> , 2022, 346, 86-97.	0.4	14
21	Mitochondrial depletion of glutaredoxin 2 induces metabolic dysfunction-associated fatty liver disease in mice. <i>Redox Biology</i> , 2022, 51, 102277.	3.9	13
22	Cytotoxic performances of new anionic cyclometalated Pt(II) complexes bearing chelated O <sup>^</sup> O ligands. <i>Applied Organometallic Chemistry</i> , 2020, 34, e5455.	1.7	12
23	Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1. <i>Pharmacological Research</i> , 2017, 122, 96-104.	3.1	11
24	Cholesterol-Lowering Action of a Novel Nutraceutical Combination in Uremic Rats: Insights into the Molecular Mechanism in a Hepatoma Cell Line. <i>Nutrients</i> , 2020, 12, 436.	1.7	11
25	Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 787-793.	1.1	8
26	Cytotoxicity of Alizarine versus Tetrabromocathecol Cyclometalated Pt(II) Theranostic Agents: A Combined Experimental and Computational Investigation. <i>Inorganic Chemistry</i> , 2022, 61, 7188-7200.	1.9	7
27	Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis – The IMPROVE Study. <i>Biomedicines</i> , 2021, 9, 841.	1.4	6
28	Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms and susceptibility to recurrent pregnancy loss. <i>Biomedical Reports</i> , 2018, 8, 172-175.	0.9	5
29	Impact of bariatric surgery-induced weight loss on circulating PCSK9 levels in obese patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 2372-2378.	1.1	5
30	Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile. <i>Atherosclerosis Plus</i> , 2021, 43, 7-9.	0.3	5
31	Evaluation of the effects of natural isoquinoline alkaloids on low density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocytes, as new potential hypocholesterolemic agents. <i>Bioorganic Chemistry</i> , 2022, 121, 105686.	2.0	5
32	PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4114.	1.8	4
33	The Emerging Role of Nutraceuticals in Cardiovascular Calcification: Evidence from Preclinical and Clinical Studies. <i>Nutrients</i> , 2021, 13, 2603.	1.7	4
34	The Modulation of PCSK9 and LDLR by Supercritical CO <sub>2</sub> Extracts of <i>Mentha longifolia</i> and Isolated Piperitone Oxide, an In Vitro Study. <i>Molecules</i> , 2021, 26, 3886.	1.7	2
35	NMR, LC-MS Characterization of <i>Rydingia michauxii</i> Extracts, Identification of Natural Products Acting as Modulators of LDLR and PCSK9. <i>Molecules</i> , 2022, 27, 2256.	1.7	2
36	Identification of patients with defects in the globin genes by analysing blood parameters and genetic study: Report of five cases. <i>Journal of Hematological Malignancies</i> , 2013, 3, .	0.0	0

#	ARTICLE	IF	CITATIONS
37	Leaf extract of morus alba reduces the expression of proprotein convertase subtilisin kexin type 9 (PCSK9) in HEPG2 cell line. <i>Atherosclerosis</i> , 2018, 275, e55.	0.4	0
38	Pcsk9 9 Induces Vascular Calcification Under Uremic Conditions: In Vitro And In Vivo Study. <i>Atherosclerosis</i> , 2019, 287, e10-e11.	0.4	0
39	Small Chemical Entities Targeting Pcsk9: Synergistic Effect With Simvastatin On Ldl Cholesterol Uptake By Hepg2 Cells. <i>Atherosclerosis</i> , 2019, 287, e36.	0.4	0
40	Tu1238 SERUM PCSK9 AS NOVEL BIOMARKER FOR INFLAMMATION AND CARDIOVASCULAR RISK IN ULCERATIVE COLITIS. <i>Gastroenterology</i> , 2020, 158, S-1029-S-1030.	0.6	0
41	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors: identification of a new class of small molecules. <i>Journal of Clinical Lipidology</i> , 2021, 15, e25.	0.6	0